CureVac (NSDQ:CVAC) has announced that its first-generation COVID-19 vaccine has passed its first interim analysis but has chosen not to share efficacy data until a statistically significant efficacy analysis is ready.
The Tübingen, Germany–headquartered company is developing two mRNA-based vaccines. The mRNA vaccines from Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) are currently two of the most popular COVID-19 vaccines in the world.
The data and safety monitoring board also concluded that there were no safety concerns linked to the CVnCoV in the HERALD study.
The company’s second-generation vaccine is known as CV2CoV, which it is developing in collaboration with GSK.
Filed Under: clinical trials, Drug Discovery, Infectious Disease